Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia

XUE Meiping; ZHENG Ruping; LIN Huie; GAN Huizhen

doi:10.3969/j.issn.1006-0111.2018.05.020

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To investigate the efficacy and safety of combination therapy with sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia. Methods 158 patients treated at endocrinology clinic in our hospital for brittle diabetes with hyperlipidemia were selected for the retrospective analysis. 78 patients received insulin alone were severed as the control group while 80 patients treated with sitagliptin and premixed insulin as the treatment group. The follow-up time was 36 weeks. The levels of HbAlc, FPG, PPG, fasting C peptide, postprandial 2 h C peptide, average difference of daily trough and peak blood glucose level (△TP), blood lipid level and hypoglycemia incidences were compared before and after treatment between two groups. Results After treatment,the levels of FPG, PPG, △TP, TC, TG and LDL-C in the combination therapy group were significantly lower than the level before treatment (P<0.05,P<0.01). Those values in the treated group were also lower than the control group (P<0.05,P<0.01). The fasting C peptide and postprandial 2 h C peptide in the combination therapy group were significantly higher than level before treatment (P<0.01).Those values were higher in the treated group compared to the control group (P<0.05). Conclusion Combination therapy of sitagliptin and premixed insulin for the treatment of brittle diabetes with hyperlipidemia can significantly improve patients' blood glucose and lipid levels with less adverse reactions.

Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia

Department of Pharmacy, No. 180 Hospital of PLA, Quanzhou 362000, China

Received Date: 2017-12-19

Rev Recd Date: 2018-03-05

Key words:

Abstract: Objective To investigate the efficacy and safety of combination therapy with sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia. Methods 158 patients treated at endocrinology clinic in our hospital for brittle diabetes with hyperlipidemia were selected for the retrospective analysis. 78 patients received insulin alone were severed as the control group while 80 patients treated with sitagliptin and premixed insulin as the treatment group. The follow-up time was 36 weeks. The levels of HbAlc, FPG, PPG, fasting C peptide, postprandial 2 h C peptide, average difference of daily trough and peak blood glucose level (△TP), blood lipid level and hypoglycemia incidences were compared before and after treatment between two groups. Results After treatment,the levels of FPG, PPG, △TP, TC, TG and LDL-C in the combination therapy group were significantly lower than the level before treatment (P<0.05,P<0.01). Those values in the treated group were also lower than the control group (P<0.05,P<0.01). The fasting C peptide and postprandial 2 h C peptide in the combination therapy group were significantly higher than level before treatment (P<0.01).Those values were higher in the treated group compared to the control group (P<0.05). Conclusion Combination therapy of sitagliptin and premixed insulin for the treatment of brittle diabetes with hyperlipidemia can significantly improve patients' blood glucose and lipid levels with less adverse reactions.

HTML

Reference (10)

[1]	VANTYGHEM MC,PRESS M. Management strategies for brittle diabetes[J]. Ann Endocrinol(Paris),2006,67(4):287-296.
[2]	AMETOV AS,KULIDZHANIAN NK. Diabetes mellitus is an independent risk factor for cardiovascular disease[J]. Ter Arkh,2012,84:91-94.
[3]	KIM D,WANG L,BECONI M,et al. (2R)-4-oxo-4-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine:a potent,orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2005,48(6):141-151.
[4]	DRUKER DJ, NAUCK MA. GLP-1R agonists(incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes[J]. Lancet, 2006, 368(3):1696-1705.
[5]	DRUCKER DJ. Enhancing incretin action for the treatment of type 2 diabetes[J]. Diabetes Care,2003,26(10):2929-2940.
[6]	LIU XM. Special complication of diabetes[M]//LIU Xinmin. Practical endocrinology. 2nd ed. Beijing:People's Military Medical Publishing House, 1997:356-358.
[7]	郭慧,刘良专,刘江华. 降脂通络软胶囊联合瑞舒伐他汀对2型糖尿病合并高血脂症患者效果观察[J]. 重庆医学,2015,44(24):3348-3349.
[8]	HOLST JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide 1[J]. Diabetes Metab Res Rev,2002,18(6):430-441.
[9]	徐晓菲,吴玉波,吴禹蒙. 西格列汀对2型糖尿病患者血脂水平影响的系统评价[J]. 中国药房,2015,26(6):784-787.
[10]	罗娜,朱妍,张真稳,等. 西格列汀联合胰岛素治疗脆性糖尿病的临床观察[J]. 中南大学学报(医学版),2015,40(10):1089-1095.

Message Board

Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia

doi: 10.3969/j.issn.1006-0111.2018.05.020

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views